GCCA invites you to join our global community to help us in the fight against the killer disease colorectal cancer which is highly treatable if diagnosed early.
Colorectal cancer (CRC) is the 2nd leading cause of cancer deaths worldwide. More than 620,000 people die each year from CRC and the number is growing. More than 1.2 million people are diagnosed with CRC each year. CRC is the 3rd most common cancer, yet it remains the most preventable major cancer through screening. Incidence rate is expected to increase by 33.5% by 2020. The economic burden of CRC is staggering, estimated to be in excess of $33,000,000,000.
In many countries around the world, there are no CRC screening programs, no access to treatments and no patient voice to effectuate change. Similarly CRC patients have no support. Even in developed and developing countries, CRC remains a huge problem. In the US, 1/3 of the number of people who should be screened are not getting tested and in Europe the problem is far worse. There are 136 million Europeans eligible for CRC screening yet only 12 million have participated. While Europe accounts for only 11% of the world population, it accounts for about 1/3 of all CRC deaths worldwide.
CRC is increasing in economically transitioning countries, including Eastern Europe, most of Asia, and in select countries in South America. CRC incidence rates worldwide increased in 27 of 51 international cancer registries studied by the IARC. Very few other countries have formal screening programs, coverage for testing or awareness programs to educate the public about the disease and how it can be prevented. Awareness of the disease, its reach, its ability to be prevented and its treatability if caught early, are the keys to changing the global problem of colon cancer.
A significant difference could be made in survival rates by raising the profile of the disease, dispelling the taboos surrounding it, encouraging early detection through screening, treating the disease at an early stage and eventually the widespread use of personalised treatments based on novel molecular targets.
Global Colon Cancer Allicance urges you to react to these predictions and inivtes you to join our alliance now!